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ABSTRACT Porcine epidemic diarrhea virus (PEDV) is a highly pathogenic alphacoronavirus. In the United States, highly viru-
lent PEDV strains cause between 80 and 100%mortality in suckling piglets and are rapidly transmitted between animals and
farms. To study the genetic factors that regulate pathogenesis and transmission, we developed a molecular clone of PEDV strain
PC22A. The infectious-clone-derived PEDV (icPEDV) replicated as efficiently as the parental virus in cell culture and in pigs,
resulting in lethal disease in vivo. Importantly, recombinant PEDV was rapidly transmitted to uninoculated pigs via indirect
contact, demonstrating virulence and efficient transmission while replicating phenotypes seen in the wild-type virus. Using re-
verse genetics, we removed open reading frame 3 (ORF3) and replaced this region with a red fluorescent protein (RFP) gene to
generate icPEDV-ORF3-RFP. icPEDV-ORF3-RFP replicated efficiently in vitro and in vivo, was efficiently transmitted
among pigs, and produced lethal disease outcomes. However, the diarrheic scores in icPEDV-ORF3-RFP-infected pigs were
lower than those in wild-type-virus- or icPEDV-infected pigs, and the virus formed smaller plaques than those of PC22A. To-
gether, these data describe the development of a robust reverse-genetics platform for identifying genetic factors that regulate
pathogenic outcomes and transmission efficiency in vivo, providing key infrastructural developments for developing and evalu-
ating the efficacy of live attenuated vaccines and therapeutics in a clinical setting.
IMPORTANCE Porcine epidemic diarrhea virus (PEDV) emerged in the United States in 2013 and has since killed 10% of U.S.
farm pigs. Though the disease has been circulating internationally for decades, the lack of a rapid reverse-genetics platform for
manipulating PEDV and identifying genetic factors that impact transmission and virulence has hindered the study of this im-
portant agricultural disease. Here, we present a DNA-based infectious-clone system that replicates the pathogenesis of circulat-
ing U.S. strain PC22A both in vitro and in piglets. This infectious clone can be used both to study the genetics, virulence, and
transmission of PEDV coronavirus and to inform the creation of a live attenuated PEDV vaccine.
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Coronaviruses are important emerging viruses that are capableof producing sudden pandemic disease outbreaks with high
morbidity, mortality, and economic losses in animal and human
populations (1). Porcine epidemic diarrhea virus (PEDV) is an
alphacoronavirus that recently emerged in the United States and
has since killed 8 million piglets, nearly 10% of all U.S. farm
piglets in 2014 (2). In the United States, newly emerged strains of
PEDV are highly virulent and cause mortality rates in suckling
piglets of between 80 and 100% (2). Clinically, pigs infected with
PEDV have severe diarrhea and vomiting, leading to death by
dehydration within a few days of infection (2–4). PEDV readily
spreads by fecal-oral transmission routes between swine, in swine
feed, and through contaminated farming and transport equip-
ment (5). A second newly discovered swine coronavirus in the
United States, designated swine deltacoronavirus (SDCV), was
discovered in Ohio and found to be closely related to coronavi-
ruses detected in Hong Kong in 2012 (6). Porcine orthoreoviruses
that are similar to strains identified in Southeast Asia have also
been detected in U.S. herds (7). It is clear that new approaches are
desperately needed to control pandemic outbreaks of swine respi-
ratory and enteric viruses.
Although the origins of PEDV remain obscure and early se-
quence studies had suggested similarity to human coronavirus
NL63, more-recent studies argue that PEDV is more closely re-
lated to several bat alphacoronaviruses identified in the United
States, South America, and Eurasia (8, 9). PEDV first emerged in
Europe in the 1970s and spread across Europe and into Asia (10).
However, it was not until late 2010 that extremely virulent forms
emerged in China (11). In the United States, phylogenetic studies
suggest that PEDV is most closely related to Chinese strain
AH2012*, although its transmission route to the United States still
remains uncertain (2, 8, 12). Since the first U.S. outbreak of PEDV
in April 2013, PEDV has rapidly spread across 34 states, Canada,
and Central America and has returned to devastate the swine in-
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dustry in Asia (13, 14). During this ongoing outbreak, new strat-
egies are desperately needed to understand pathogenic mecha-
nisms and the functions of viral genes and to provide new
technologies to combat this disease.
PEDV appears to recognize CD13, an aminopeptidase N pro-
tein, as a receptor for entry into pig cells, as well as the sugar
coreceptors heparan sulfate andN-acetylneuraminic acid (15, 16).
PEDV can infect multiple cell types in vitro, including swine, hu-
man, primate, and bat cells, suggesting the possibility of adapta-
tion and spread to other species (15). The PEDV genome is com-
posed of 28,000 nucleotides (nt) encoding seven known open
reading frames (ORFs) expressed from both genomic and sub-
genomic mRNAs (17). Subgenomic mRNAs are arranged in a
nested fashion from the 3= end of the genome. PEDV encodes the
traditional coronavirus structural proteins: a receptor-binding
spike glycoprotein (S), the envelope protein (E), the membrane
glycoprotein (M), and the nucleocapsid protein (N). The spike
glycoprotein is a type I membrane glycoprotein composed of S1
and S2 external domains, a transmembrane domain, a C-terminal
cytoplasmic domain, and a signal peptide. The S protein plays a
role in virulence, growth adaptation, receptor binding, and virus-
cell membrane fusion (18, 19). E of PEDV (PEDV-E) upregulates
stress pathways in the host cell, induces antiapoptotic factors, and
is important for viral budding (20). PEDV-N induces cell stress
and prevents apoptosis through similar pathways and prolongs
the host cell’s S phase (21). Additionally, PEDV contains at least
three additional ORFs: ORF1a, ORF1b, and ORF3. ORF1a and -b
encode two viral proteases that process these large precursor poly-
proteins into 16 nonstructural proteins, including the viral repli-
case and associated RNA-modifying enzymes that are critical for
full-length and subgenomic positive- and negative-strand RNA
synthesis (22). ORF3 regulates virus production and encodes an
ion channel important for viral fitness but is not required for viral
replication in vitro (23, 24).
In this study, we generated the first infectious cDNA clone of a
virulent North American PEDV strain, PC22A (25). Parental
genomic and ORF3 deletion recombinant viruses were generated
using the infectious cDNA clone system; the latter was also engi-
neered to express red fluorescent protein (RFP). Both recombi-
nant viruses are replication competent in vitro and pathogenic in
neonatal gnotobiotic (Gn) piglets. Parental and recombinant vi-
ruses were efficiently transmitted to uninoculated pigs via indirect
contact, allowing for genetic studies into the molecular mecha-
nisms regulating virus transmission and pathogenesis. The avail-
ability of an infectious clone for PEDV will allow us further op-
portunities to understand gene function and genetic variants in
PEDV pathogenesis and transmission, leading to better-informed
design of vaccines and therapeutics.
RESULTS
Design of an infectious PEDV clone. We have developed molec-
ular clones for several highly pathogenic swine and human coro-
naviruses, using class II restriction endonucleases, to directionally
assemble a full-length cDNA viral genome from a set of sequen-
tially designed smaller cDNAs (26–31). To develop a molecular
clone for PEDV, the highly virulent PC22A strain (Fig. 1A) was
sequenced and synthesized as six contiguous PEDV subclones
designated A to F (Fig. 1B). Subclones A/B, B/C, C/D, and D/E are
joined by unique SapI restriction endonuclease cleavage sites (at
nucleotide positions 4071, 8287, 12016, and 16941, respectively)
that allow for directional assembly into a full-length cDNA with-
out alteration of the viral amino acid sequence. Subclones E and F
are joined at a unique BsaI site at nucleotide position 22504. In
subclone F, a single BsaI restriction site in PEDV-PC22A was re-
moved by introducing a silent mutation at position 24337, effec-
tively marking the recombinant genome (Fig. 1C). Thus, each
fragment contains a unique set of class II restriction enzyme sites
flanking the genomic sequence that allow for unique 3-nt over-
FIG 1 Schematic of the full-length PEDV genome and construction of the infectious PEDV cDNA clone and mutants. (A) PEDV genome, including ORF1a,
ORF1b, and the spike (S), ORF3, envelope (E), membrane (M), and nucleocapsid (N) genes. (B) cDNA fragments comprising icPEDV. Restriction sites joining
fragments are noted. (C) The BsaI site was removed from icPEDV, as indicated by the A to G nucleotide change in yellow. (D) PEDV-ORF3-RFP. Restriction
sites were used to replace ORF3 with tomato-red and the ORF3 transcription regulatory sequence (TRS). 5= and 3= UTR, 5= and 3= untranslated regions.
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hangs between each fragment. This specificity allows for system-
atic, efficient, and directional assembly of the complete PEDV
genome by in vitro ligation. The PEDV A fragment contains a T7
start site, whereas the F fragment terminates in 22 A residues,
allowing for in vitro transcription and capping of a polyadenylated
full-length transcript.
PEDV-ORF3 is an accessory ORF encoding a putative ion
channel protein that is oftentimes deleted from some natural iso-
lates or following in vitro passage, suggesting that it encodes non-
essential functions in vitro and/or in vivo (24). To generate a fluo-
rescently marked PEDV genome mutant, ORF3 in the PEDV F
fragment was replaced with red fluorescent protein (RFP), named
tomato-red (Fig. 1D). The mutant was created using native re-
striction enzyme recognition sequences that allowed for the pres-
ervation of the ORF3 transcription regulatory sequence (TRS),
which regulates subgenomic RNA expression (Fig. 1D).
Recovery of recombinant viruses. To isolate recombinant
wild-type and RFP-expressing recombinant PEDVs, each plasmid
fragment was digested with noted restriction enzymes, purified,
and ligated to create a full-length PEDV cDNA genome. Using the
T7 RNA polymerase, full-length transcripts were synthesized in
vitro as previously described by our group (26, 30). As previous
swine and human coronavirus infectious clones displayed im-
proved recovery rates and replication efficiency in the presence
of the supplemented N gene transcript (26, 30), capped
PEDV-N gene transcripts were mixed with the full-length
genomic transcripts prior to their electroporation into Vero
cells. Within 24 to 48 h postelectroporation, subgenomic
recombinant-virus mRNA could be detected via reverse
transcription-PCR (RT-PCR). After we isolated recombinant
virus from pig intestinal contents after inoculation, wild-type
and recombinant viruses replicated to titers that approached or
exceeded 1  104 PFU/ml in Vero cells, equivalent to titers
commonly reported in the literature (Fig. 2A). A recombinant
infectious-clone-derived PEDV (icPEDV) produced a plaque
morphology (Fig. 2B) similar to that of the parental strain and
formed syncytia characteristic of PEDV in culture (Fig. 2C).
Notably, icPEDV-ORF3-RFP displayed a reduced plaque size
compared to that of either PC22A or icPEDV (Fig. 2B), indic-
ative that ORF3 may be important for in vitro growth of the
virus and suggestive of possible attenuation of the ORF3 dele-
tion mutant. At 48 and 72 h postelectroporation with icPEDV-
ORF3-RFP, fluorescent red cells were seen in cell culture,
both within individual cells and within larger syncytia
(Fig. 2D).
Characterizationof recombinant viruses.To evaluate protein
expression in our recombinant PEDV, we cloned and expressed
PEDV-S and PEDV-N in Venezuelan equine encephalitis virus
strain 3526 virus replicon particles (VRP) and isolated VRP-
PEDV-S and VRP-PEDV-N. The VRP were inoculated into the
footpads of mice, and polyclonal PEDV-N and PEDV-S antisera
were collected after a day 21 boost. Using Western blot techniques,
we confirmed the presence of the 180-/90- and ~50-kDa PEDV-S
and PEDV-N proteins, respectively, in cells infected with icPEDV,
icPEDV-ORF3-RFP, and parental PEDV in vitro (Fig. 3A). Thus,
molecularly derived viruses have protein expression phenotypes
similar to those of the parental virus.
To further confirm the presence of the recombinant virus post-
electroporation, we reverse transcribed genomic RNA from viri-
ons in the culture media and then sequenced them to demonstrate
the presence of the distinguishing BsaI cloning site in infectious-
clone viruses (Fig. 3B). Additionally, we sequenced the leader-
containing subgenomic mRNA transcripts to ensure that both our
recombinant viruses and their parental strain shared the wild-type
transcription regulatory sequence (TRS) required for normal
coronavirus replication and growth kinetics (Fig. 3C). Together,
these data definitively demonstrate that both recombinant clones
generated replicating recombinant virus in vitro.
icPEDV replication and pathogenesis in Gn piglets. PEDV
PC22A is highly pathogenic in newborn piglets and is rapidly
transmitted to littermates. To determine if icPEDV replicated pa-
rental PEDV PC22A in vivo pathology and transmission pheno-
types, gnotobiotic (Gn) pigs were orally inoculated with icPEDV
(passage 0 [P0]), icPEDV-ORF3-RFP (P0), or PC22A (P3) and
housed with uninfected indirect-contact pigs (Table 1). Chal-
lenged animals demonstrated fecal viral RNA shedding, and diar-
rhea started 1 to 3 days postinfection (dpi) in all three virus groups
(Fig. 4A; Table 1). Importantly, uninoculated indirect-contact
pigs within each group demonstrated both robust virus shedding
and diarrhea, confirming the transmissibility of both PC22A and
the recombinant virus (Fig. 4B). All three viruses replicated to
similar peak titers (11 to 13 log10 genomic equivalents [GE]/ml).
However, PC22A and icPEDV group pigs had more-severe diar-
rhea (highest fecal score of 3) than icPEDV-ORF3-RFP group
pigs (highest score of 2). The day of harvest for each piglet was
dependent on clinical fecal scores or occurred upon the death of
the piglet. Notably, days of harvest varied both between virus types
and within virus groups. Because of the animal numbers in each
group and because of the variation within each PEDV group, the
day of harvest cannot be used as a reliable indicator of the relative
degree of viral virulence or attenuation. The pathogenesis of
icPEDV in Gn pigs also replicated the pathogenic phenotype of
PEDV strain PC21A, which had been collected from the same
swine farm on the same day as PC22A (4).
Histopathological examination showed severe villous atrophy
in PEDV PC22A- and icPEDV-inoculated pigs and moderate-to-
severe villous atrophy in icPEDV-ORF3-RFP-infected pigs
(Fig. 5A). The villous height/crypt depth (VH/CD) ratio of the
jejunum of a mock-inoculated pig was significantly higher than
those of PC22A-, icPEDV-, and icPEDV-ORF3-RFP-infected
pigs (P  0.05) (Table 1). Immunohistochemistry (IHC) for
PEDV-N confirmed the presence of recombinant virus through-
out the small intestine (duodenum, jejunum, and ilium) in both
icPEDV- and icPEDV-ORF3-RFP-infected pigs (Fig. 5B; Ta-
ble 2). In addition, icPEDV antigens were detected in the large
intestine (colon).
These results indicate that the cell culture supernatants of
icPEDV and icPEDV-ORF3-RFP contained infectious recombi-
nant virus particles that replicated well in gnotobiotic pigs. While
the recombinant icPEDV replicated the clinical phenotypes of pa-
rental PC22A in vivo, icPEDV-ORF3-RFP infection resulted in a
partial attenuation in pigs based on lower diarrhea scores. The
rapid infection of contact pigs suggests efficient transmission of
icPEDV and icPEDV-ORF3-RFP, replicating both parental
PC22A and circulating U.S. strain transmission phenotypes.
DISCUSSION
Emerging viruses pose a considerable threat to humans and soci-
ety by causing morbidity and mortality in human populations or
causing significant losses in important food sources and trade,
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leading to economic instability and loss of critical protein sources,
especially in poor rural populations. Porcine epidemic diarrhea
virus is a serious livestock pathogen that is causing significant
economic losses in the swine industry internationally. To date,
over a billion piglets have died globally. Live vaccine has been used
historically to combat PEDV outbreaks in Asia; however, live vac-
cines available today are ineffective in preventing outbreaks of
circulating pandemic strains, including U.S. outbreak strains, and
have not significantly reduced the global disease burden (14).
Other important nidovirus infections of swine include transmis-
sible gastroenteritis virus (TGEV), its related respiratory variant
designated porcine respiratory coronavirus (PRCV), and porcine
reproductive and respiratory disease virus (PRRSV), which have
caused major economic losses to the swine industry since the late
1980s (32–34). In addition to PEDV, an emerging coronavirus,
porcine deltacoronavirus, has recently been reported in swine,
demonstrating the possibility of continued emergent threats to
this important food industry (6, 35). Given the apparent increase
in the number of new swine viruses identified over the past
30 years, it seems clear that management practices and/or other
changes in the ecosystem are providing an environmental setting
that promotes the emergence of new viral pathogens for the swine
industry. If so, these data document the need for the development
of new, rapid-response intervention platforms for disease control
in critical livestock populations that are centrally linked to human
health. In this article, we describe the first molecular clone for a
FIG 2 Growth of icPEDV clones isolated from in vivo small intestine samples. (A) Titers of viral stocks isolated from small intestinal contents at the noted
passages, harvested 2 dpi; (B) representative plaques (arrows) of mock-infected cells and cells infected with the parental PC22A strain, icPEDV, and icPEDV-
ORF3-RFP, from left to right, at 2 dpi; (C) fluorescence microscopy of passage 0 icPEDV-ORF3-RFP in cell culture at 1 dpi; (D) syncytium formation of
passage 0 icPEDV-ORF3-RFP.
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highly pathogenic U.S. strain of PEDV, PC22A, isolated from an
outbreak in Ohio in June 2013 (25). Both the parental PEDV
PC22A strain and its derivative recombinant cloned virus were
genetically stable and fully pathogenic in neonatal gnotobiotic
pigs, demonstrating that icPEDV provides not only a strategy that
allows for the systematic evaluation of the role of viral genes in
pathogenesis, tropism, and virulence but also a translational plat-
form for the development of rationally attenuated live virus vac-
cines. In addition, we have constructed a recombinant PEDV that
bears an indicator gene, the RFP gene, which allows for rapid
evaluation of antiviral efficacy and neutralizing antibody levels by
means of high-throughput cell culture systems.
Recently, a molecular clone for a high-growth tissue culture
variant of a 2010 Thai isolate, designated PEDVAVCT12, was re-
ported in the literature (36). In contrast to our findings, full-
length recombinant PEDVAVCT12 could not be isolated unless
ORF3 expression had been ablated, either by naturally occurring
deletions or by insertion of an indicator gene in this location.
Interestingly, naturally occurring deletions also removed 7 amino
acids from the C terminus of the S protein, similar to deletions
described with other tissue culture strains, like PEDV strain
CHM2013 (36). At this time, the discrepancy between the two
laboratory results is intriguing and most likely is directly related to
the backbone sequence of the two isolates and/or the difficulties
associated with culturing clinical isolates of PEDV in vitro. Tissue
culture PEDVAVCT12 replicates 2 to 3 logs more efficiently than
wild-type PEDV PC22A and icPEDV in culture, and trypsin is also
required to culture the latter isolates in vitro. Future studies may
well reveal the emergence of similar tissue culture adaptations
during serial passage of our highly virulent PEDV PC22A and
icPEDV in culture. Importantly, pathogenic outcomes in vivo
were not evaluated using the heavily tissue culture-adapted
PEDVAVCT12 strain, so the utility of this recombinant virus in
evaluating pathogenic outcomes and/or the role of tissue culture-
adaptive mutations in virulence are uncertain at best. Although an
exact infectious dose of our recombinant viruses was not deter-
mined from these studies,1 PFU of PEDV PC22A is sufficient to
cause disease in piglets (37).
Little information is available regarding the molecular mecha-
FIG 3 Confirmatory studies of the infectious PEDV clone. (A) Western blot
for PEDV spike (PEDV-S), before (180 kDa) and after (90 kDa) cleavage with
trypsin, and nucleocapsid (PEDV-N). Protein was isolated from Vero cells
infected with PC22A, icPEDV, or icPEDV-ORF3-RFP, which was harvested
and sequenced 2 dpi. (B) An altered BsaI cloning site is conserved (yellow
highlighting) after viral passage in piglets. (C) The transcription regulatory
sequence (TRS) in the leader region of PEDV subgenomic transcripts is con-
served between the wild type and icPEDV. The sequence is highlighted in
yellow.
TABLE 1 Summary of PEDV replication and pathogenesis in Gn pigsb
Group
No. of
pigs Pig
Age at
inoculation
(days)
Inoculation
or contacta
Onset of fecal RNA
shedding/diarrhea
(dpi or dpc)
Highest fecal scorec/
fecal RNA shedding
titer (GE/ml)
Age (dpi) of piglet
at euthanasia
(day)
Jejunum
VH/CD ratio
icPEDV 5 1 19 Inoculation 2/2 3/12.9 ND ND
2 19 Contact 2/4 3/13.2 24 (5) 1.2 0.2
3 16 Inoculation 1/2 3/11.5 20 (4) 1.4 0.2
4 16 Inoculation 1/2 3/12.0 21 (5) 1.3 0.2
5 16 Contact 1/2 3/11.5 21 (5) 3.1 1.5
icPEDV-ORF3-RFP 3 6 14 Inoculation 1/1 2/11.6 16 (2) 2.2 0.1
7 14 Contact 2/5 2/11.6 21 (7) 1.0 0.0
8 14 Inoculation 1/3 2/10.8 17 (3) 2.7 0.4
PC22A 4 9 18 Inoculation 1/1 3/13.0 19 (1) 1.4 0.3
10 18 Contact 2/3 3/11.8 21 (3) 1.3 0.1
11 26 Inoculation 1/1 3/11.8 27 (3) ND
12 26 Contact 1/2 3/11.12 21 (7) ND
Mock infected 1 11 NA NA NA 1/NA 19 6.8 0.9
a Pigs 2, 5, 7, and 10 were exposed by indirect contact to the pigs which were housed in the same isolator through small holes drilled into the stainless steel divider. The panel was
located between the 2 pigs in the shared pig tub isolator unit.
b ND, not done because pig 1 was used for hyperimmune serum production; NA, not available; VH/CD, villous height/crypt depth.
c Fecal scores were as follows: 0, normal; 1, pasty stool; 2, semiliquid diarrhea; and 3, liquid diarrhea.
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nisms governing efficient coronavirus pathogenesis and transmis-
sion between hosts. Importantly, icPEDV and icPEDV-ORF3-
RFP are efficiently transmitted to cohoused littermates, providing
a potential platform for investigating the genetic mechanisms reg-
ulating efficient transmission between hosts. While similar studies
using highly pathogenic influenza viruses in ferrets are highly con-
troversial because of potential human-pandemic concerns (38),
identifying genetic factors that attenuate transmission frequency
offer a powerful tool to improve the safety and efficacy of live
attenuated coronavirus vaccines, especially given the high-
animal-density manufacturing approaches used in the swine in-
dustry. Such studies may also provide significant insights into the
fundamental principles and genetic functions that influence the
transmission efficiency of other highly pathogenic human coro-
naviruses, like severe acute respiratory syndrome coronavirus
(SARS-CoV) and Middle East respiratory syndrome coronavirus
(MERS-CoV).
PEDV infection is most devastating in neonatal and suckling
piglets, necessitating vaccines that target lactogenic immunity
through the vaccination of pregnant sows and gilts. Piglets do not
attain passive immunity preparturition but instead receive IgG-
and IgA-based lactogenic immunity from colostrum and milk,
respectively. With both TGEV and PEDV, sows infected with live
virulent virus transferred more protective immunity against viral
challenge in their nursing piglets than sows infected with attenu-
ated or inactivated virus (39). The USDA has granted conditional
licenses to two PEDV manufacturers to date. The Harris vaccine
uses an attenuated Venezuelan equine encephalitis virus (VEEV)
vaccine strain replicon particle expressing the PEDV spike protein
(40). The second is a parenterally killed virus vaccine made by
Zoetis (41). Both are used to immunize pregnant sows and gilts.
Their efficacy and ability to protect against various circulating
U.S. strains are still under evaluation. We note that the VRP plat-
form described in our paper was based on a biosafety level 2
(BSL2) nonselect agent, a VEEV strain designated 3526, which has
been used in animal and human trials (42–44). In contrast to other
VEEV replicon platforms, VEEV 3526 retains wild-type E1 and E2
glycoproteins, which efficiently target dendritic cells (45, 46), but
lacks E3 sequences. This deletion of E3 confers an attenuated phe-
notype in vivo. VEEV 3526 expressing appropriate S glycoprotein
genes provides robust protection against other coronaviruses, like
SARS-CoV, MERS-CoV, and HKU5-S (47–49). Using VEEV 3526
structural genes allows for recovery of high-titer VRP encoding
PEDV-S and/or -N under BSL2 conditions. It remains unclear
whether the VRP 3526 platform will prove sufficiently robust to
induce in sows lactogenic immunity capable of protecting suck-
ling piglets (49). Future experiments will have to be designed and
implemented to test the relative efficacies of VRP vaccines, killed-
whole-virus vaccines, or future live attenuated-virus vaccines.
Importantly, no live-virus vaccine is currently available in the
United States, and historical live vaccines have not been effective
in combating current U.S. or Asian strains (14). Robust studies
using SARS-CoV have identified several viral genes, including the
E protein, the ExoN nsp14 RNA proofreading machinery, and the
2-O-methyltransferase nsp16 replicase, as high-priority targets for
rational attenuation of coronaviruses (50–52). Because coronavi-
FIG 4 icPEDV mimics wild-type PEDV infection in gnotobiotic piglets. Gnotobiotic piglets were infected orally with 2 ml of the PEDV supernatant, and an
uninoculated piglet was cohoused with them to determine transmission. All animals succumbed to illness or were euthanized due to illness at their final time
points. (A) Mean RT-qPCR titers of fecal samples and fecal scores after viral inoculation. The line represents mean values, with individual piglet values shown by
points. (B) RT-qPCR titers of fecal samples and fecal scores in cohoused transmission control piglets, days after contact with the inoculated piglets whose results
are represented in panel A. The limit of detection in real-time (rt) RT-PCR figures (threshold cycle 37) is represented by a red line.
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ruses undergo RNA recombination at high frequency and encode
an exonuclease function (53, 54), recombination repair and rever-
sion to wild-type virus is a pressing concern when designing live
attenuated coronavirus vaccines. However, our laboratory has de-
veloped strategies to prevent recombination repair that limit the
capacity of rationally designed live attenuated virus to revert to the
wild-type virus sequence (55). Effective vaccines are increasingly
important, as new strains are identified in the United States and
circulating strains continue to devastate herds. The infectious
clone platform allows for rapid construction of genetically modi-
fied PEDV variants to evaluate the function of antigenic variation
on neutralization phenotypes and can be used for the rational
design of a live virus vaccine. This platform also allows for incor-
poration of genetic changes to enhance the replication of the virus
in vitro for more efficient production of attenuated vaccines.
Globally, humans have experienced coronavirus outbreaks with
increasing frequency, including outbreaks of two new human
coronaviruses in the last 15 years, notably, SARS-CoV and MERS-
CoV (56). Human and animal coronaviruses share similar struc-
tural proteins and replication dynamics. Currently, no transmis-
sion model for these important human pathogens is available. The
neonatal pig model described in this study can provide a surrogate
transmission model for human coronaviruses. Separately, the
study of coronavirus transmission in its original host in a BSL2
climate affords the opportunity to safely and accurately research a
FIG 5 Histology and IHC staining of icPEDV-infected pig intestine. Gnotobiotic piglets were orally inoculated with 2 ml of PEDV. A contact control piglet was
cohoused with an inoculated piglet(s) to determine transmission. All animals succumbed to illness or were euthanized due to illness at their final time points
(PEDV, 1 dpi; icPEDV, 4 dpi; icPEDV-ORF3-RFP, 7 dpi; contact control, 4 dpi). All images show representative histological slides of jejunum specimens from
mock-infected or infected animals. Histology of mock-, icPEDV-, or icPEDV-ORF3-RFP-infected animals, showing H&E staining and immunohistochemistry
(IHC) staining (B) for PEDV nucleocapsid (N) protein using mouse anti-PEDV-N. A specimen from a contact piglet infected by icPEDV is also shown. Cell
fusion and vacuolation were noted at the villus tips (arrows). IHC staining of icPEDV- or icPEDV-ORF3-RFP-infected animals whose results are represented
in panel A is shown.
TABLE 2 Summary of IHC staining in infected pigs
Group Pig dpi
IHC signal intensity scorea
Duodenum Jejunum Ileum Colon
icPEDV 2 5 0 3 3 1
3 4 2 3 3 1
4 5 1 3 2 2
5 5 1 3 2 1
icPEDV-ORF3-RFP 6 2 0 1 1 0
7 7 1 2 3 0
8 3 0 2 2 0
a The IHC signal of PEDV antigen was scored as 0 to 3 according to the percentage of
villous enterocytes within the section showing a positive signal. A score of 0 means that
there were no positive cells, and scores of 1, 2, and 3 mean that30%, 30 to 60%, and
60% of villous enterocytes showed a positive signal, respectively.
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family of viruses that is devastating animal and human popula-
tions. It is possible that genetic manipulation of recombinant
PEDVs will enable studies that can significantly enhance our un-
derstanding of the role of coronavirus genetics in the transmis-
sion, virulence, and pathologies that are central to both animal
and human health and disease prevention.
In this article, we describe a reverse-genetics platform for a
highly virulent U.S. PEDV strain that causes lethal disease in new-
born piglets, allowing for the future identification of attenuating
mutations and virulence alleles. In parallel, we have developed
indicator viruses that can be used for high-throughput neutraliza-
tion assays or to evaluate the impact of antivirals. This reverse-
genetics system will allow for quick and robust PEDV genetic
manipulation in a clinical North American isolate, allowing for
in-depth study of viral replication and pathogenesis, which are
essential for the development of safe and robust live attenuated-
virus vaccines.
MATERIALS AND METHODS
Viruses and cells. The wild-type PC22A strain of PEDV (passage 4) was
cultured on Vero cells, as described previously (25). Cells were grown in
growth medium containing Dulbecco’s modified Eagle medium
(DMEM) (Life Technologies) supplemented with 5% fetal bovine serum
(Life Technologies) and 1% antibiotic-antimycotic (Gibco). Virus was
grown in Vero cells in maintenance medium, which was DMEM supple-
mented with 10 g/ml trypsin (Life Technologies), 0.3% tryptose phos-
phate broth (Sigma), and 1% antibiotic-antimycotic (Life Technologies).
Cells were kept in a humidified incubator at 37°C and 5% CO2.
Assembly of full-length recombinant PEDV. The icPEDV clone was
designed using six separate fragments (ordered from Bio Basic) flanked
with unique flanking class II restriction sites that leave nonpalindromic
overhangs. Sequences were ordered based on PC22A passage 4 sequence
(GenBank accession number km392224.1). All cDNA subclones were
grown in the pcXL-TOPO vector. In fragment E, a naturally occurring
BsaI site was removed by introducing a silent mutation in order to prevent
interference with assembly of the full-length infectious clone. All PEDV
fragments were sequenced after transfection into bacterial culture to en-
sure sequence fidelity. The PEDV fragments were digested using restric-
tion sites designated in Fig. 1, run on a 1% agarose gel, excised, and
purified using a QIAquick gel extraction kit (Qiagen). The PEDV frag-
ments were mixed and ligated overnight at 4°C using T4 DNA ligase
(Roche). Ligated fragments were phenol-chloroform extracted, and full-
length T7 RNA transcripts were generated as described in the mMessage
mMachine manufacturer protocol (Ambion), but we allowed the reaction
to run at 30°C for 3 h and then at room temperature for 2 h. In addition,
SP6 PEDV-N gene transcripts were generated from the PCR-purified
PEDV-N gene sample using a 4:1 ratio of cap to GTP (Ambion).
To generate the ORF3 deletion RFP construct, the tdTomato gene was
amplified by PCR with flanking PEDV sequence and then inserted using
native restriction sites into PEDV-F. PEDV-F-ORF3-RFP was cultured
and sequenced to ensure seamless replacement of ORF3 with RFP con-
taining the ORF3 TRS.
In vitro transfection. Genome-length and N RNA transcripts were
mixed with 800 l of Vero-BI cells (1  107 cells/ml) in phosphate-
buffered saline (PBS) and then added to an electroporation cuvette. Three
pulses of 450 V at 50F were used to transfect the cells with a Gene Pulser
II electroporator (Bio-Rad). The cells were allowed to recover for 10 min
at room temperature and then were transferred to a 75-cm2 flask in
growth medium at 37°C for 2 h, after which time the cells were washed and
incubated in cell culture medium. Trypsin was added to the culture at
5 g/ml 12 h postelectroporation to assist in virus recovery and spread.
Sequence analysis identification of marker mutations. Virus har-
vested from small intestinal contents was grown in Vero-BI cell culture for
48 h. Virion RNA was harvested from the supernatant using the QIAamp
viral RNA minikit (Qiagen). After purification, viral cDNA was generated
with Superscript II reverse transcriptase (Life Technologies) as previously
described by our group (26). To demonstrate the presence of the marker
mutation, the icPEDV BsaI mutation site was amplified by PCR using
primers 5= TCCAAGCCATTTCTAGTTCTATT 3= and 5= TGACACAAC
AAAGATGAGAACA 3=. PCR amplicons were gel purified and then se-
quenced using primers 5= TCAGGCTAGCAGGAAGTTAG 3= and 5= AG
GTCAACTAGTGTGTTGTTGATAT 3=.
Western blot and transcript analysis. Virus from infected animals
was cultured in Vero-BI cell culture for 48 h and washed with PBS, and
intracellular RNA was harvested from cells using NP-40 buffer (150 mM
NaCl, 1% Triton X-100, 50 mM Tris, pH 8.0) for Western blots or TRIzol
(Life Technologies) for RNA analysis. cDNA from viral RNA transcripts
was generated using Superscript II reverse transcriptase (Life Technolo-
gies) and PCR amplified using primer pairs from the PEDV leader se-
quence and nucleocapsid gene. PCR products were separated on a 1%
agarose gel and visualized on a Dark Reader transilluminator (Clare
Chemical Research).
For Western blot analysis, protein from infected cells was denatured in
4 Laemmli buffer (Bio-Rad) at 95°C for 6 min and then separated on
gradient 4 to 15% Mini-Protean precast gels (Bio-Rad) prior to electro-
phoretic transfer of the proteins to polyvinylidene difluoride (PVDF)
membranes (Bio-Rad). To detect PEDV antigens, blots were first blocked
with 5% milk in Tris-buffered saline with Tween 20 (TBST) and then
probed with a polyclonal mouse serum (diluted 1:200) from mice which
had been immunized with Venezuelan equine encephalitis virus replicon
particles (VRP) expressing PEDV nucleocapsid (N) or spike (S) glycopro-
tein. Blots were developed using GE Healthcare Amersham ECL Western
blotting detection reagents and exposed to film for imaging.
Animal studies. Four groups of 2- to 3-week-old gnotobiotic (Gn)
pigs were used to examine the replication and pathogenesis of icPEDV-
and icPEDV-ORF3-RFP-derived viruses in vivo and compared with
PC22A- and mock-infected positive and negative controls, respectively
(Table 1). Piglets were orally inoculated with 2 ml of icPEDV or icPEDV-
ORF3-RFP culture supernatants after transfection (P0) (1.0 
102 PFU/ml) or with the tissue culture-adapted PC22A strain at passage
level 3 (P3) at a dose of 5.8 log10 PFU/pig. To investigate transmission, pigs
2, 5, 7, and 10 were cohoused in the same isolator as infected pigs but were
separated by a stainless steel divider that contained small holes which
allowed only indirect contact between the groups. Animals were moni-
tored daily for clinical signs of disease, including diarrhea and vomiting.
Rectal swabs were collected for scoring fecal denseness (scores: 0 nor-
mal; 1  pasty stool; 2  semiliquid diarrhea; and 3  liquid diarrhea)
and for enumerating fecal viral RNA shedding by RT-quantitative PCR
(RT-qPCR). Except for one pig in the icPEDV group, which was kept long
term for the production of hyperimmune serum, the Gn pigs were eutha-
nized at acute infection phase (within 5 days postinoculation [dpi] or
7 days postcontact with the inoculated pigs [dpc]) for histopathological
examinations. At necropsy, small and large intestinal contents were col-
lected and tested by RT-qPCR for viral RNA levels and for infectious virus
by plaque assay. The different sections of the small intestine (duodenum,
jejunum, ilium) and large intestine (cecum and colon) were collected for
histopathological examination and stained with hematoxylin and eosin
(H&E) stain. The derivation and maintenance of Gn pigs, sample collec-
tion and testing, and histopathology were performed as previously de-
scribed (25, 57). All the animal use protocols employed in this study were
reviewed and approved by the Agricultural Animal Care and Use Com-
mittee of The Ohio State University.
IHC staining. The immunohistochemistry (IHC) staining procedure
was optimized as described previously (37) using the non-biotin-
polymerized horseradish peroxidase (HRP) system (BioGenex Laborato-
ries, San Ramon, CA). Briefly, intestinal tissue sections from each pig were
deparaffinized and rehydrated in graded ethanol to PBS (pH 7.4). Antigen
retrieval and unmasking were performed by treatment with 0.05% pro-
nase E (Sigma-Aldrich, St. Louis, MO) for 20 min. The endogenous per-
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oxidase activity was quenched with 3% hydrogen peroxide (Sigma) for
20 min. Then, the sections were incubated in Power Block solution (Bio-
Genex) for 30 min at room temperature. Mouse monoclonal antibody
anti-PEDV nucleocapsid protein (N) (SD6-29; a gift from E. Nelson and
S. Lawson, South Dakota State University) was applied to each section at
4°C overnight. After two washes in PBS, a commercial Super Sensitive
IHC detection system (BioGenex) was used. Finally, these sections were
counterstained with Mayer’s hematoxylin (BioGenex) and dehydrated,
and coverslips were added. The IHC signal of PEDV antigen was scored as
0 to 3 according to the percentage of villous enterocytes within the section
showing a positive signal. Scores were as follows: 0 indicated that there
were no positive cells and 1, 2, and 3 indicated that30%, 30 to 60%, and
60% of villous enterocytes showed a positive signal, respectively.
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